In this study, we have demonstrated that in a high CVD-risk population, such as in those with chronic kidney disease (CKD), these changes will bring alterations in lipid metabolism, particularly in circulating apolipoproteins [28]; in particular, a statistically significant decrease in ApoA-I, ApoA-II, ApoB-100, ApoE, ApoM, and ApoL1 and a statistically significant increase in ApoA-IV, ApoC-III, and ApoH. This evidence concerns the gene APOM and chronic kidney disease.